Menu Search
Equities

Sirona Biochem Corp

SRBCF:PKC

Sirona Biochem Corp

Actions
  • Price (USD)0.046
  • Today's Change0.00 / 0.00%
  • Shares traded7.85k
  • 1 Year change-46.39%
  • Beta--
Data delayed at least 15 minutes, as of May 21 2024 16:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem’s proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin).

  • Revenue in CAD (TTM)36.35k
  • Net income in CAD-2.65m
  • Incorporated2006
  • Employees--
  • Location
    Sirona Biochem Corpc/o WeWork, 595 Burrard St.VANCOUVER V7X 1L4CanadaCAN
  • Phone+1 (604) 641-4466
  • Fax+1 (604) 608-5471
  • Websitehttps://www.sironabiochem.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.